Ian Hagemann, MD, PhD

Expert oncologist Ian Hagemann, MD, PhD, shares insight into the process of making a differential diagnosis of low-grade serous ovarian cancer in light of adjacent disease and available IHC testing.

Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.

Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.

The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.

Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.

Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.